Cell membrane chromatographic column for screening active substances with bone strengthening effect and application of cell membrane chromatographic column
By using a cell membrane chromatography column carrying hBMP7 expression gene, the problem of lack of targetedness and specificity in screening bone-strengthening pharmacodynamic substances in the prior art is solved, and efficient and low-cost bone-strengthening pharmacodynamic substances are achieved, filling the problem of high-efficiency and low-cost bone-strengthening pharmacodynamic substances. The market is vacant and has good application prospects.
Patent Information
- Application Number
- CN202411233931.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art lacks targeted and specificity in screening bone-strengthening pharmacodynamic substances, and cannot quickly and effectively screen out specific bone-strengthening pharmacodynamic substances, resulting in low drug selection and use efficiency, increasing treatment time and economic burden.
Using a cell membrane chromatography column carrying the hBMP7 expression gene, a cell membrane suspension that stably expresses hBMP7 is filled into the C18 chromatography column to form a bilayer stationary phase of the cell membrane phospholipids, which is used to screen active substances with bone-strengthening effect to achieve specific drug effects. Accurate screening of substances.
This method can efficiently and accurately screen out active substances with bone-strengthening effect. It has low cost, simple technology, and can be produced on a large scale, with controllable quality, fill market gaps, and reduce investment thresholds and risks.
Smart Images

Figure CN118987693A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of chromatographic separation, and in particular relates to a cell membrane chromatographic column for screening active substances with bone strengthening effect and application thereof. Background Art
[0002] Osteoporosis is a systemic bone disease caused by a variety of reasons, which leads to decreased bone density and bone quality, destruction of bone microstructure, increased bone brittleness, and easy fracture. Osteopenia and osteoporosis are different stages of the same disease, and both show a decrease in bone content. The bone mass reduction in osteoporosis is more serious. Osteopenia is the previous stage of osteoporosis, which can also indicate that the symptoms of osteoporosis are more serious than osteopenia. The low bone mass rate in people aged 40 to 49 in my country reached 32.9%. Low bone mass and early osteoporosis usually have no obvious clinical manifestations. In addition, the primary medical and health institutions are not capable of preventing and treating osteoporosis, and the aging of society is aggravated. Osteoporosis brings a heavy economic burden to patients' families and society. Therefore, quickly screening out specific drugs for bone strengthening and determining the selection and use of drugs can reduce blind medication and shorten the treatment time of patients.
[0003] Due to technical limitations, the existing technology still has major shortcomings in the rapid screening of bone strengthening medicinal substances and cannot meet actual needs. For example, the use of zebrafish models to efficiently screen the toxic taste of bone strengthening pills can achieve large-scale screening, but lacks specificity. Another example is based on nuclear magnetic resonance spectroscopy (1 H The active ingredients of Bushen Zhuanggu Decoction that promote testosterone synthesis were screened by NMR metabolomics combined with molecular docking technology. It can indeed affect the key protein expressed by the effector target. The molecular docking technology was used to screen out the chemical components that bind well to this key protein from the active components; however, this method can only infer the approximate structure of the substance and has no specificity. Summary of the invention
[0004] In view of the problem that the existing methods for screening bone-strengthening medicinal substances lack pertinence and specificity, the present invention provides a cell membrane chromatography column and application thereof for screening active substances with bone-strengthening effects. The method is highly pertinent, can screen out specific medicinal substances, has low cost and more streamlined technology.
[0005] The present invention is achieved through the following technical solutions: A cell membrane chromatography column for screening active substances with bone strengthening effect. The cell membrane chromatography column is filled with a cell membrane chromatography stationary phase carrying an hBMP7 expression gene and is prepared by the following method: (1) Transfect rat BMSCs with a lentiviral vector carrying the hBMP7 expression gene, and screen for cell lines that stably express hBMP7; (2) culturing a cell line stably expressing hBMP7 to obtain a cell culture medium; (3) preparing the cell culture fluid into a cell membrane suspension; (4) Fill the cell membrane suspension to C 18 In the chromatographic column, the cell membrane phospholipid bilayer self-fuses to form a stationary phase, and after incubation for 8 to 24 hours, a cell membrane chromatographic column for screening active substances with bone strengthening effects is obtained.
[0006] Furthermore, the preparation method of the cell membrane suspension in step (3) is as follows: the cell culture medium in step (2) is washed with PBS, repeatedly frozen and thawed at -20°C for 2 to 3 times, PBS is added for one centrifugation to obtain a cell suspension, the precipitate is discarded, the supernatant is centrifuged twice, and the precipitate after centrifugation is taken and vortexed with PBS to prepare a cell membrane suspension.
[0007] Furthermore, in step (3), the first centrifugation condition is 1000 r / min for 10 min, and the second centrifugation condition is 10000 r / min for 20 min at 4°C.
[0008] Furthermore, the concentration of the cell membrane suspension is 0.5-1.5 mg / mL.
[0009] Furthermore, the cell concentration in the cell culture medium in step (2) is 3-6×10 7 Pieces / mL.
[0010] In the present invention, the cell membrane chromatography column for screening active substances with bone strengthening effect is used in screening active substances with bone strengthening effect.
[0011] Furthermore, the cell membrane chromatography column for screening active substances with bone strengthening effect is used in screening active substances with bone strengthening effect in antler glue.
[0012] Furthermore, the peptide sequence of the bone-strengthening active substance in antler glue is GDTPTLQLEEVDPK.
[0013] Beneficial Effects The cell membrane chromatography column for screening active substances with bone strengthening effect of the present invention is based on cell membrane-C 18 As a stationary phase, the stationary phase surface contains abundant hBMP7. When used to screen active substances, hBMP7 can specifically bind to active substances, thereby separating and screening active substances from samples (such as deer antler polypeptides).
[0014] The preparation method of the cell membrane chromatography column of the present invention comprises the following steps: ultrasonically disrupting cells to obtain a cell membrane suspension, slowly adding the cell membrane suspension to a chromatography column filled with silica gel, and self-fusion of the cell membrane phospholipid bilayer to obtain a cell membrane chromatography stationary phase. The method maintains the integrity of the cell membrane, the quaternary spatial structure of the membrane receptor, and the biological activity of the membrane receptor to the maximum extent. When the cell membrane chromatography column of the present invention is used to screen active substances, it is more streamlined than existing screening methods and technologies, has lower production costs, can be mass-produced, has controllable quality, excellent performance, reasonable costs, can fill market gaps, has large market demand, low production costs, and mature preparation processes. At the same time, it can fully guarantee production quality and safety, effectively reduces investment thresholds and investment risks, and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 It is a schematic diagram of the results of restriction enzyme electrophoresis analysis of hBMP7 gene; Figure 2 It is a schematic diagram of the double enzyme digestion electrophoresis analysis results of the pCDH vector; Figure 3 Schematic diagram of fluorescence detection after rat BMSCs were transfected with lentiviral vector carrying hBMP7 expression gene; Figure 4 Schematic diagram of the expression of Hbmp-7 gene level after rat BMSCs were transfected with lentiviral vector carrying hBMP7 expression gene; Figure 5 Schematic diagram of Western blot detection of hBMP7 protein expression in rat BMSCs after lentiviral vector carrying hBMP7 expression gene was transfected, where total protein loading amount: 20 μg; Lane 1: Normal blank group (Normal); Lane 2: No-load group (No-load); Lane 3: Transfection group (BMP7); Figure 6 This is the total positive ion current diagram of the mass spectrometry column of antler glue cell membrane; Figure 7 This is the total negative ion current diagram of the mass spectrometry column of antler glue cell membrane; Figure 8 The sequence information of the antler peptide GDTPTLQLEEVDPK on proteins P51745 and D5KXX5; Fig. 9 This is the mass spectrum information of the antler glue peptide segment GDTPTLQLEEVDPK (m / z 771.3912). DETAILED DESCRIPTION
[0016] The present invention will be further described below in conjunction with the embodiments. However, the scope of the present invention is not limited to the following embodiments. It will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention.
[0017] The instruments, reagents, materials, etc. involved in the following embodiments, unless otherwise specified, are all conventional instruments, reagents, materials, etc. in the prior art and can be obtained through regular commercial channels. The experimental methods, detection methods, etc. involved in the following embodiments, unless otherwise specified, are all conventional experimental methods, detection methods, etc. in the prior art.
[0018] Example 1 (1) Obtaining hBMP7 target gene and digesting the backbone vector (pCDH) The hBMP7 target gene fragment was double-digested with restriction endonucleases NheI and BamHI. The results of enzyme electrophoresis analysis are shown in the figure. Figure 1 As shown in the figure, the theoretical size of the restriction enzyme band is 1200 bp, and the target gene fragment is observed at the position of 1296 bp; the target band appears, the band is clear, and the restriction enzyme fragment is consistent with the theoretical length, indicating that the target gene is successfully obtained. The backbone vector (pCDH) is double-digested with restriction endonucleases NheI and BamHI. The schematic diagram of the double-digestion electrophoresis analysis results is shown in the figure. Figure 2 As shown, after double enzyme digestion, a linear single band was presented, and a vector fragment was observed at the 8190 bp position, indicating that it was successfully cut.
[0019] (2) Ligation of hBMP7 target gene and backbone vector (pCDH) after double restriction digestion Use the 120 μL ligation system in the table below to connect the amplified hBMP7 target gene and the backbone vector (pCDH) with T4 ligase, and connect overnight at 4°C to obtain a lentiviral vector (recombinant vector) carrying the hBMP7 expression gene; Table 1 Composition of 20 μL ligation system .
[0020] (3) Identification of lentiviral vectors carrying the hBMP7 expression gene The results of colony PCR identification showed that most of the cloned connections were positive, and the subsequent sequencing results showed that there were no base deletions and mutations in the sequence, and the plasmid was constructed correctly.
[0021] (4) Transfection of rat BMSCs (bone marrow mesenchymal stem cells) with a lentiviral vector carrying the hBMP7 expression gene: 1) Cell culture: Rat BMSCs were routinely cultured using BASAL (ORIcell) culture medium at 37°C and 5% CO2, with a serum concentration of 10%, a penicillin concentration of 100 U / ml, and a streptomycin concentration of 0.1 mg / ml. When the cells entered the logarithmic growth phase, they were washed three times with PBS and then digested with trypsin. After the cells became round, the culture medium was added again to terminate the digestion, and the cells were repeatedly pipetted to form a single cell suspension; 2) Puromycin working concentration screening: The above single cell suspension was plated in a 24-well plate at 6 x 10 4 Cells / well were plated at a density of 100 μg / mL, and sufficient wells were plated for subsequent gradient experiments; cells were incubated overnight, and screening medium was prepared - fresh medium containing different concentrations of puromycin (0-15 μg / mL, at least 5 gradients); after cells were incubated overnight, screening medium was added and cells were incubated; fresh screening medium was replaced every 3 days, and cells were monitored daily to observe the proportion of surviving cells; the minimum antibiotic concentration refers to the lowest screening concentration that kills the used cells within 1-4 days from the start of antibiotic screening; the results show that the optimal working concentration of puromycin for BMSCs is 2 ug / ml; BMSCs were cultured at 6 x 10 4 The cells were inoculated into a 24-well plate at a density of cells / well and incubated overnight. The culture medium was removed and the lentiviral vector carrying the expression gene of hBMP7 was added to the well plate. Complete culture medium was added after 6 hours and replaced with fresh complete culture medium after 24 hours. Puromycin working solution (2ug / ml) was added after 48 hours. After the cells were fully grown, they were passaged and puromycin was continuously added to the culture medium. After three passages, the cells were observed under a fluorescence microscope until all the non-luminous cells died. The rat BMSCs transfected with the lentiviral vector carrying the expression gene of hBMP7 were obtained and expanded cultured and cryopreserved. The schematic diagram of fluorescence detection is shown in the figure. Figure 3 As shown, the results showed that the recombinant hBMP7 lentivirus was successfully inserted into the chromosome of BMSC cells.
[0022] (5) RT-PCR detection of hBMP7 gene expression in transfected cells Total RNA of BMSCs in the hBMP7 overexpression group and the blank control group was collected, and the expression of hBMP7 was detected by QPCR. The expression of hBMP7 gene level in rat BMSCs after the lentiviral vector carrying the hBMP7 expression gene was transfected is shown in the figure. Figure 4 As shown, the results showed that hBMP7 could be stably overexpressed in the stably transfected cells, which was 126 times overexpressed compared with the blank control group.
[0023] (6) Western blot detection of hBMP7 protein expression after transfection Western blot was used to detect the expression of hBMP7 in three groups of cells (overexpression group, empty group, and normal control group). The expression diagram of hBMP7 protein after rat BMSCs were transfected with lentiviral vector carrying the hBMP7 expression gene is shown in Figure 5 As shown, the total protein loading amount: 20 μg; Lane 1: normal blank group; Lane 2: empty group; Lane 3: transfection group; Figure 5 It can be seen that a single protein immunoreactive band of about 55 kD was observed in all three groups, which is consistent with the molecular size of hBMP7 protein reported in the literature. Taking 43 kD β-actin as the internal reference, the grayscale analysis and statistical analysis of the expression of β-actin in the three groups showed that the experimental group (1.169±0.013) expressed BMP7 protein more than the negative control group (0.011±0.004) and the blank control group (0.010±0.003), and the differences were statistically significant (P<0.05). There was no statistically significant difference between the empty group and the blank group (P>0.05). The above results indicate that BMP7 protein level is highly expressed after rat BMSCs are transfected with hBMP7 target gene virus, and the secretion of BMP7 in bone marrow mesenchymal stem cells in the control group is extremely low.
[0024] Example 2 Preparation of cell membrane chromatography column for screening active substances with bone strengthening effect: (1) As in step (4) of the example, rat BMSCs (bone marrow mesenchymal stem cells) were transfected with a lentiviral vector carrying the expression gene of hBMP7, and a cell line stably expressing hBMP7 was screened; (2) Cultivate a cell line stably expressing hBMP7 to obtain a cell culture medium. The cell concentration in the cell culture medium is 4×10 7 Pieces / mL; (3) The cell culture medium in step (2) was washed three times with PBS, repeatedly frozen and thawed at -20°C for three times, and centrifuged once with PBS (1000 r / min for 10 min) to obtain a cell suspension. The precipitate was discarded, and the supernatant was centrifuged twice (10000 r / min for 20 min at 4°C). After centrifugation, the precipitate was taken and vortexed with PBS to prepare a cell membrane suspension. The concentration of the cell membrane suspension was 0.5-1.5 mg / mL.
[0025] (4) Fill the cell membrane suspension to C 18 In the chromatographic column (Water ACQUITY UPLC HSS C18 chromatographic column (2.1 mm×100 mm, 1.8 μm)), the cell membrane phospholipid bilayer self-fused to form a stationary phase, and after incubation for 12 hours, a cell membrane chromatographic column for screening active substances with bone strengthening effects was obtained, which was stored at 4° C. for future use.
[0026] Example 3 The cell membrane chromatography column for screening active substances with bone strengthening effect (Example 2) was used to screen active substances with bone strengthening effect from deer antler glue.
[0027] (1) Preparation of antler glue samples Crush the antler slices and place them in a round-bottom flask, add 5 times the amount of distilled water, and boil; take the glue juice every 3 hours, add water and boil again, boil twice in total, combine the glue juice, filter the residue, and concentrate it under vacuum at 50°C; cool to room temperature to obtain antler glue, sterilize by radiation, and store at 4°C. Take the prepared antler glue and put it in a high-speed universal grinder, pass it through a 120-mesh sieve to obtain antler glue powder; accurately weigh 50 mg of antler glue powder, place it in a 25mL volumetric flask, add distilled water to make up the volume, use ultrasonic extraction for 15 minutes, and make up the weight loss with distilled water to obtain antler glue aqueous solution (2mg / mL).
[0028] (2) Take 5 mL of antler glue aqueous solution (2 mg / mL), filter it with a 0.22 μm microporous filter membrane, slowly load it onto a C18 chromatographic column (2.1 mm × 100 mm, 1.8 μm), and elute it with 10 mL of water and 10 mL of acetonitrile, respectively. Collect the water eluate and the acetonitrile eluate and place them in a conical flask. Concentrate the eluate under reduced pressure, make up to volume with water and acetonitrile in a 5 mL volumetric flask, respectively, and filter it with a 0.22 μm microporous filter membrane to obtain the antler glue aqueous solution sample and the antler glue acetonitrile solution sample.
[0029] (3) UPLC-Q-Exactive Orbitrap MS experimental conditions Chromatographic conditions: the cell membrane chromatography column for screening active substances with bone strengthening effect in Example 2, mobile phase acetonitrile (A)-0.1% acetic acid aqueous solution (B), gradient elution (0 min, 95% B; 3 min, 95% B; 9 min, 50% B; 28 min, 5% B; 28.1 min, 95% B; 31 min, 0% B), flow rate 0.3 mL·min-1, injection volume 40 μL, column temperature 35°C.
[0030] Mass spectrometry conditions: the ion source was a heated electrospray ion source (HESI), the scanning mode was a full scan of the primary mass spectrometer combined with an automatic triggering of the secondary mass spectrometer scanning mode (FullMS / dd-MS2), the scanning range was m / z80-1500, the primary mass spectrometer resolution was 70000, the secondary mass spectrometer resolution was 17500, the capillary voltage in the positive ion mode was 3.8 kV, the capillary voltage in the negative ion mode was 3 kV, the capillary temperature and the vaporization temperature were both 350 °C, the sheath gas and the auxiliary gas were both N2, the sheath gas flow rate and the auxiliary gas flow rate were 45 arb and 15 arb, respectively, and the voltage of the high-pressure annular ion introduction device (S-LensRFLevel) was 55. The step collision energy was 20, 40, and 60 eV.
[0031] Example 4 Screening and identification of active components promoting ossification in antler glue 1) Software Analysis The spectra were analyzed using Xcalibur 4.3 (Thermo Fisher Scientific, USA) software.
[0032] 2) Maxquant parameter settings The RAW data generated by Xcalibur were searched using Maxquant software (version 2.4.0.0). The Uniprot database included in the red deer and sika deer protein library Red deer (reviewed, 32 sequences, downloaded on 2023-05-05) and Sika deer (reviewed, 14 sequences, downloaded on 2023-05-05) was used as the search database, and the experimental parameters were set to NoFraction and Label free quantification, and other parameters were the default values.
[0033] 3) Perseus parameter settings The proteinGroups.txt and peptides.txt data generated by Maxquant were processed using Perseus software (version 2.0.10.0), and contaminating proteins (potential contamiant) and proteins with unique peptide>1 were filtered out in order to obtain independent peptides.
[0034] 4) Bioinformatics analysis of antler gum peptides The probability of biological activity of peptides can be predicted through the online website PeptideRanker (http: / / distilldeep.ucd.ie / PeptideRanker / ). The toxicity of peptides can be predicted through the online website ToxIBTL (https: / / server.wei-group.net / ToxIBTL / ProcessServlet). The hemolytic activity of peptides can be predicted using the online website Hemopred (http: / / codes.bio / hemopred / ), and the sensitization of peptides can be predicted using the online website Algpred2.0 (https: / / webs.iiitd.edu.in / raghava / algpred / submission.html); The water solubility of the identified peptide can be predicted through the online prediction website (https: / / pepcalc.com-Peptide calculator); the instability index and pI value of the peptide can be predicted using the Expasy ProtParam tool (https: / / web.expasy.org / protparam), and the chemical molecular formula of the peptide can also be obtained. The instability index can be used to preliminarily determine whether the peptide is stable in the experiment. A result less than 40 is stable, and a result greater than 40 may be unstable.
[0035] 5) Mass spectrometry detection of active substances: In the positive and negative ion modes, the total positive ion chromatograms and total negative ion chromatograms of the deer antler glue aqueous solution and acetonitrile solution are shown as follows: Figure 6 and Figure 7 As shown, Maxquant was used to identify the peptides in the spectrum. The specific peptides identified by Maxquant are shown in Table 2.
[0036] Table 2 Identification information of antler glue peptides After using Perseus to remove common potential contaminants and peptides with unique peptide>1, the peptide GDTPTLQLEEVDPK was obtained with an FDR below 1% and good identification reliability. The peptide was identified as part of the protein P51745 sequence by the red deer and sika deer protein sequence library that had been manually verified in the Uniprot database. In addition, another protein with this peptide was found in the red deer and sika deer protein sequence library that had not been manually verified, and its Protein ID was D5KXX5. The sequence information of the peptide GDTPTLQLEEVDPK on proteins P51745 and D5KXX5 can be found in Figure 8P51745 was identified as interleukin-1β by the PDB protein structure database, while D5KXX5 was not identified. The mass spectrum of GDTPTLQLEEVDPK is shown in Fig. 9 .
[0037] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention.
Claims
1. A cell membrane chromatography column for screening active substances with bone strengthening effect, characterized in that: The cell membrane chromatography column is filled with a cell membrane chromatography stationary phase carrying the hBMP7 expression gene and is prepared by the following method: (1) Transfect rat BMSCs with a lentiviral vector carrying the hBMP7 expression gene, and screen for cell lines that stably express hBMP7; (2) culturing a cell line stably expressing hBMP7 to obtain a cell culture medium; (3) preparing the cell culture fluid into a cell membrane suspension; (4) Fill the cell membrane suspension to C 18 In the chromatographic column, the cell membrane phospholipid bilayer self-fuses to form a stationary phase, and after incubation for 8 to 24 hours, a cell membrane chromatographic column for screening active substances with bone strengthening effects is obtained.
2. The cell membrane chromatography column for screening active substances having bone strengthening effect according to claim 1, characterized in that: The preparation method of the cell membrane suspension in step (3) is as follows: the cell culture medium in step (2) is washed with PBS, repeatedly frozen and thawed at -20°C for 2 to 3 times, PBS is added for one centrifugation to obtain a cell suspension, the precipitate is discarded, the supernatant is centrifuged twice, and the precipitate after centrifugation is taken and vortexed with PBS to prepare a cell membrane suspension.
3. The cell membrane chromatography column for screening active substances having bone strengthening effect according to claim 2, characterized in that: In step (3), the first centrifugation condition is 1000 r / min for 10 min, and the second centrifugation condition is 10000 r / min for 20 min at 4°C.
4. The cell membrane chromatography column for screening active substances having bone strengthening effect according to claim 1, characterized in that: The concentration of the cell membrane suspension is 0.5~1.5 mg / mL.
5. The cell membrane chromatography column for screening active substances having bone strengthening effect according to claim 1, characterized in that: The cell concentration in the cell culture medium in step (2) is 3-6×10 7 Pieces / mL.
6. Use of the cell membrane chromatography column for screening active substances having bone strengthening effect according to any one of claims 1 to 5 in screening active substances having bone strengthening effect.
7. The use according to claim 6, characterized in that: The cell membrane chromatography column for screening active substances with bone strengthening effect is used in screening active substances with bone strengthening effect in antler glue.
8. The use according to claim 6, characterized in that: The peptide sequence of the bone-strengthening active substance in deer antler glue is GDTPTLQLEEVDPK.
Citation Information
Patent Citations
Detection method of adenovirus-mediated gene transfection autologous bone marrow mesenchymal stem cells
CN106282233A
Induction of osteogenesis by delivering BMP encoding RNA
CN107405412A
Method for screening osteogenesis regulator
WO2014185416A1
